oxaliplatin + cetuximab + bevacizumab + panitumumab + irinotecan + leucovorin + 5-fluorouracil

This complex multi-agent regimen is an intensified treatment strategy developed by UNICANCER for patients with liver-only metastatic colorectal cancer. Evaluated in the SULTAN Phase II clinical trial, the regimen combines a cytotoxic backbone of FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil) with oxaliplatin, which is specifically administered via Hepatic Arterial Infusion (HAI) to maximize local drug concentration in the liver. The protocol further incorporates targeted monoclonal antibodies, including bevacizumab (anti-VEGF) and EGFR inhibitors (cetuximab or panitumumab), to provide a comprehensive attack on tumor proliferation and angiogenesis. This aggressive approach is designed to convert initially unresectable liver metastases into a resectable state, potentially offering a curative surgical option for patients who have failed or had insufficient responses to standard induction chemotherapy.

Other names

oxaliplatin + cetuximab + bevacizumab + panitumumab + irinotecan + leucovorin + 5-Fluorouracil-UNICANCER-colorectal cancer metastaticHAI Oxaliplatin plus systemic FOLFIRI and biologics